{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T01:33:12Z","timestamp":1792978392513,"version":"4.5.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T00:00:00Z","timestamp":1791244800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T00:00:00Z","timestamp":1791244800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100010425","name":"Tri-Service General Hospital","doi-asserted-by":"publisher","award":["CN115-03"],"award-info":[{"award-number":["CN115-03"]}],"id":[{"id":"10.13039\/501100010425","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1007\/s12282-026-01921-9","type":"journal-article","created":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T11:04:01Z","timestamp":1791284641000},"page":"1419-1432","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Target trial emulation of first-line ribociclib versus palbociclib in hormone receptor-positive, HER2-negative metastatic breast cancer: a comparative effectiveness study"],"prefix":"10.1007","volume":"33","author":[{"given":"Xiaoyi","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Po-Huang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei-Cheng","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong-Jie","family":"Jhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hsin-Yu","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li-Ting","family":"Kao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tina Yi-Jin","family":"Hsieh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming-Shen","family":"Dai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Na","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6061-5168","authenticated-orcid":false,"given":"Cho-Hao","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,6]]},"reference":[{"key":"1921_CR1","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1016\/j.breast.2016.10.001","volume":"31","author":"F Cardoso","year":"2017","unstructured":"Cardoso F, Costa A, Senkus E, Aapro M, Andr\u00e9 F, Barrios CH, et al. 3rd ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 3). Breast. 2017;31:244\u201359.","journal-title":"Breast"},{"issue":"4","key":"1921_CR2","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1056\/NEJMoa1903765","volume":"381","author":"SA Im","year":"2019","unstructured":"Im SA, Lu YS, Bardia A, Harbeck N, Colleoni M, Franke F, et al. Overall survival with ribociclib plus endocrine therapy in breast cancer. N Engl J Med. 2019;381(4):307\u201316.","journal-title":"N Engl J Med"},{"issue":"6","key":"1921_CR3","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1056\/NEJMoa1911149","volume":"382","author":"DJ Slamon","year":"2020","unstructured":"Slamon DJ, Neven P, Chia S, Fasching PA, De Laurentiis M, Im SA, et al. Overall survival with ribociclib plus fulvestrant in advanced breast cancer. N Engl J Med. 2020;382(6):514\u201324.","journal-title":"N Engl J Med"},{"issue":"10","key":"1921_CR4","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1056\/NEJMoa2114663","volume":"386","author":"GN Hortobagyi","year":"2022","unstructured":"Hortobagyi GN, Stemmer SM, Burris HA, Yap YS, Sonke GS, Hart L, et al. Overall survival with ribociclib plus letrozole in advanced breast cancer. N Engl J Med. 2022;386(10):942\u201350.","journal-title":"N Engl J Med"},{"issue":"20","key":"1921_CR5","doi-asserted-by":"publisher","first-page":"1925","DOI":"10.1056\/NEJMoa1607303","volume":"375","author":"RS Finn","year":"2016","unstructured":"Finn RS, Martin M, Rugo HS, Jones S, Im SA, Gelmon K, et al. Palbociclib and letrozole in advanced breast cancer. N Engl J Med. 2016;375(20):1925\u201336.","journal-title":"N Engl J Med"},{"issue":"9","key":"1921_CR6","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1200\/JCO.23.00137","volume":"42","author":"DJ Slamon","year":"2024","unstructured":"Slamon DJ, Di\u00e9ras V, Rugo HS, Harbeck N, Im SA, Gelmon KA, et al. Overall survival with palbociclib plus letrozole in advanced breast cancer. J Clin Oncol. 2024;42(9):994\u20131000.","journal-title":"J Clin Oncol"},{"issue":"113","key":"1921_CR7","first-page":"65","volume":"21","author":"L Spring","year":"2016","unstructured":"Spring L, Bardia A, Modi S. Targeting the cyclin D-cyclin-dependent kinase (CDK) 4\/6-retinoblastoma pathway with selective CDK 4\/6 inhibitors in hormone receptor-positive breast cancer: rationale, current status, and future directions. Discov Med. 2016;21(113):65\u201374.","journal-title":"Discov Med"},{"key":"1921_CR8","unstructured":"Novartis Pharmaceuticals. KISQALI (ribociclib) tablets, oral. Prescribing information. Updated September; 2025."},{"key":"1921_CR9","unstructured":"Pfizer Inc. IBRANCE (palbociclib) capsules, oral. Prescribing information. Revised June; 2026."},{"issue":"1","key":"1921_CR10","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1007\/s10549-018-4901-0","volume":"172","author":"C Messina","year":"2018","unstructured":"Messina C, Cattrini C, Buzzatti G, Cerbone L, Zanardi E, Messina M, et al. CDK4\/6 inhibitors in advanced hormone receptor-positive\/HER2-negative breast cancer: a systematic review and meta-analysis of randomized trials. Breast Cancer Res Treat. 2018;172(1):9\u201321.","journal-title":"Breast Cancer Res Treat"},{"issue":"7","key":"1921_CR11","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1016\/j.annonc.2025.03.023","volume":"36","author":"L Provenzano","year":"2025","unstructured":"Provenzano L, Dieci MV, Curigliano G, Giuliano M, Botticelli A, Lambertini M, et al. Real-world effectiveness comparison of first-line palbociclib, ribociclib or abemaciclib plus endocrine therapy in advanced HR-positive\/HER2-negative BC patients: results from the multicenter PALMARES-2 study. Ann Oncol. 2025;36(7):762\u201374.","journal-title":"Ann Oncol"},{"issue":"1","key":"1921_CR12","doi-asserted-by":"publisher","first-page":"104103","DOI":"10.1016\/j.esmoop.2024.104103","volume":"10","author":"HS Rugo","year":"2025","unstructured":"Rugo HS, Layman RM, Lynce F, Liu X, Li B, McRoy L, et al. Comparative overall survival of CDK4\/6 inhibitors plus an aromatase inhibitor in HR+\/HER2- metastatic breast cancer in the US real-world setting. ESMO Open. 2025;10(1):104103.","journal-title":"ESMO Open"},{"issue":"7","key":"1921_CR13","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1002\/cncr.34675","volume":"129","author":"RK Goyal","year":"2023","unstructured":"Goyal RK, Chen H, Abughosh SM, Holmes HM, Candrilli SD, Johnson ML. Overall survival associated with CDK4\/6 inhibitors in patients with HR+\/HER2- metastatic breast cancer in the United States: a SEER-Medicare population-based study. Cancer. 2023;129(7):1051\u201363.","journal-title":"Cancer"},{"issue":"8","key":"1921_CR14","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1093\/aje\/kwv254","volume":"183","author":"MA Hern\u00e1n","year":"2016","unstructured":"Hern\u00e1n MA, Robins JM. Using big data to emulate a target trial when a randomized trial is not available. Am J Epidemiol. 2016;183(8):758\u201364.","journal-title":"Am J Epidemiol"},{"key":"1921_CR15","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.jclinepi.2016.04.014","volume":"79","author":"MA Hern\u00e1n","year":"2016","unstructured":"Hern\u00e1n MA, Sauer BC, Hern\u00e1ndez-D\u00edaz S, Platt R, Shrier I. Specifying a target trial prevents immortal time bias and other self-inflicted injuries in observational analyses. J Clin Epidemiol. 2016;79:70\u20135.","journal-title":"J Clin Epidemiol"},{"issue":"3","key":"1921_CR16","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1080\/00273171.2011.568786","volume":"46","author":"PC Austin","year":"2011","unstructured":"Austin PC. An introduction to propensity score methods for reducing the effects of confounding in observational studies. Multivar Behav Res. 2011;46(3):399\u2013424.","journal-title":"Multivar Behav Res"},{"issue":"10","key":"1921_CR17","doi-asserted-by":"publisher","first-page":"e297","DOI":"10.1371\/journal.pmed.0040297","volume":"4","author":"JP Vandenbroucke","year":"2007","unstructured":"Vandenbroucke JP, von Elm E, Altman DG, G\u00f8tzsche PC, Mulrow CD, Pocock SJ, et al. Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): explanation and elaboration. PLoS Med. 2007;4(10):e297.","journal-title":"PLoS Med"},{"issue":"10","key":"1921_CR18","doi-asserted-by":"publisher","first-page":"e1001885","DOI":"10.1371\/journal.pmed.1001885","volume":"12","author":"EI Benchimol","year":"2015","unstructured":"Benchimol EI, Smeeth L, Guttmann A, Harron K, Moher D, Petersen I, et al. The REporting of studies Conducted using Observational Routinely-collected health Data (RECORD) statement. PLoS Med. 2015;12(10):e1001885.","journal-title":"PLoS Med"},{"key":"1921_CR19","unstructured":"World Medical Association. WMA Declaration of Helsinki \u2013 ethical principles for medical research involving human participants. Adopted by the 18th WMA General Assembly, Helsinki, Finland, June 1964; last amended by the 75th WMA General Assembly, Helsinki, Finland, October 2024."},{"issue":"3","key":"1921_CR20","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1097\/EDE.0b013e3181d61eeb","volume":"21","author":"M Lipsitch","year":"2010","unstructured":"Lipsitch M, Tchetgen Tchetgen E, Cohen T. Negative controls: a tool for detecting confounding and bias in observational studies. Epidemiology. 2010;21(3):383\u20138.","journal-title":"Epidemiology"},{"issue":"24","key":"1921_CR21","doi-asserted-by":"publisher","first-page":"2597","DOI":"10.1001\/jama.2016.17700","volume":"316","author":"BF Arnold","year":"2016","unstructured":"Arnold BF, Ercumen A. Negative control outcomes: a tool to detect bias in randomized trials. JAMA. 2016;316(24):2597\u20138.","journal-title":"JAMA"},{"issue":"1","key":"1921_CR22","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1093\/biomet\/70.1.41","volume":"70","author":"PR Rosenbaum","year":"1983","unstructured":"Rosenbaum PR, Rubin DB. The central role of the propensity score in observational studies for causal effects. Biometrika. 1983;70(1):41\u201355.","journal-title":"Biometrika"},{"issue":"4","key":"1921_CR23","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1016\/0197-2456(96)00075-X","volume":"17","author":"M Schemper","year":"1996","unstructured":"Schemper M, Smith TL. A note on quantifying follow-up in studies of failure time. Control Clin Trials. 1996;17(4):343\u20136.","journal-title":"Control Clin Trials"},{"issue":"5","key":"1921_CR24","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1037\/a0036515","volume":"82","author":"KM Green","year":"2014","unstructured":"Green KM, Stuart EA. Examining moderation analyses in propensity score methods: application to depression and substance use. J Consult Clin Psychol. 2014;82(5):773\u201383.","journal-title":"J Consult Clin Psychol"},{"issue":"4","key":"1921_CR25","doi-asserted-by":"publisher","first-page":"268","DOI":"10.7326\/M16-2607","volume":"167","author":"TJ VanderWeele","year":"2017","unstructured":"VanderWeele TJ, Ding P. Sensitivity analysis in observational research: introducing the E-value. Ann Intern Med. 2017;167(4):268\u201374.","journal-title":"Ann Intern Med"},{"issue":"3","key":"1921_CR26","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1007\/s40265-020-01461-2","volume":"81","author":"CL Braal","year":"2021","unstructured":"Braal CL, Jongbloed EM, Wilting SM, Mathijssen RHJ, Koolen SLW, Jager A. Inhibiting CDK4\/6 in breast cancer with palbociclib, ribociclib, and abemaciclib: similarities and differences. Drugs. 2021;81(3):317\u201331.","journal-title":"Drugs"},{"issue":"81","key":"1921_CR27","doi-asserted-by":"publisher","first-page":"35226","DOI":"10.18632\/oncotarget.26215","volume":"9","author":"S Kim","year":"2018","unstructured":"Kim S, Tiedt R, Loo A, Horn T, Delach S, Kovats S, et al. The potent and selective cyclin-dependent kinases 4 and 6 inhibitor ribociclib (LEE011) is a versatile combination partner in preclinical cancer models. Oncotarget. 2018;9(81):35226\u201340.","journal-title":"Oncotarget"},{"issue":"10","key":"1921_CR28","doi-asserted-by":"publisher","first-page":"2624","DOI":"10.3324\/haematol.2020.256313","volume":"106","author":"B Maurer","year":"2021","unstructured":"Maurer B, Brandstoetter T, Kollmann S, Sexl V, Prchal-Murphy M. Inducible deletion of CDK4 and CDK6 \u2013 deciphering CDK4\/6 inhibitor effects in the hematopoietic system. Haematologica. 2021;106(10):2624\u201332.","journal-title":"Haematologica"},{"key":"1921_CR29","doi-asserted-by":"publisher","first-page":"175883592312058","DOI":"10.1177\/17588359231205848","volume":"15","author":"D Pavlovic","year":"2023","unstructured":"Pavlovic D, Niciforovic D, Papic D, Milojevic K, Markovic M. CDK4\/6 inhibitors: basics, pros, and major cons in breast cancer treatment with specific regard to cardiotoxicity\u2014a narrative review. Ther Adv Med Oncol. 2023;15:17588359231205848.","journal-title":"Ther Adv Med Oncol"},{"issue":"19","key":"1921_CR30","doi-asserted-by":"publisher","first-page":"e273","DOI":"10.1161\/CIR.0000000000000527","volume":"136","author":"KE Sandau","year":"2017","unstructured":"Sandau KE, Funk M, Auerbach A, Barsness GW, Blum K, Cvach M, et al. Update to practice standards for electrocardiographic monitoring in hospital settings: a scientific statement from the American Heart Association. Circulation. 2017;136(19):e273\u2013344.","journal-title":"Circulation"},{"key":"1921_CR31","doi-asserted-by":"publisher","first-page":"e68256","DOI":"10.2196\/68256","volume":"27","author":"KE Trinkley","year":"2025","unstructured":"Trinkley KE, Simon ST, Rosenberg MA. Impact of an alert-based inpatient clinical decision support tool to prevent drug-induced long QT syndrome: large-scale, system-wide observational study. J Med Internet Res. 2025;27:e68256.","journal-title":"J Med Internet Res"},{"issue":"6","key":"1921_CR32","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1093\/oncolo\/oyae004","volume":"29","author":"RG Borroni","year":"2024","unstructured":"Borroni RG, Bartolini M, Gaudio M, Jacobs F, Benvenuti C, Gerosa R, et al. Ribociclib-induced cutaneous adverse events in metastatic HR+\/HER2- breast cancer: incidence, multidisciplinary management, and prognostic implication. Oncologist. 2024;29(6):484\u201392.","journal-title":"Oncologist"},{"key":"1921_CR33","doi-asserted-by":"publisher","first-page":"102086","DOI":"10.1016\/j.ctrv.2020.102086","volume":"90","author":"A Desnoyers","year":"2020","unstructured":"Desnoyers A, Nadler MB, Kumar V, Saleh R, Amir E. Comparison of treatment-related adverse events of different cyclin-dependent kinase 4\/6 inhibitors in metastatic breast cancer: a network meta-analysis. Cancer Treat Rev. 2020;90:102086.","journal-title":"Cancer Treat Rev"},{"key":"1921_CR34","doi-asserted-by":"publisher","first-page":"175883591879332","DOI":"10.1177\/1758835918793326","volume":"10","author":"M Thill","year":"2018","unstructured":"Thill M, Schmidt M. Management of adverse events during cyclin-dependent kinase 4\/6 (CDK4\/6) inhibitor-based treatment in breast cancer. Ther Adv Med Oncol. 2018;10:1758835918793326.","journal-title":"Ther Adv Med Oncol"}],"container-title":["Breast Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12282-026-01921-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12282-026-01921-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12282-026-01921-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T01:02:11Z","timestamp":1792976531000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12282-026-01921-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,6]]},"references-count":34,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["1921"],"URL":"https:\/\/doi.org\/10.1007\/s12282-026-01921-9","relation":{},"ISSN":["1340-6868","1880-4233"],"issn-type":[{"value":"1340-6868","type":"print"},{"value":"1880-4233","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,6]]},"assertion":[{"value":"3 June 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All authors declare no conflicts of interest.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"<b>Declarations<\/b>"}},{"value":"This study was approved by the Institutional Review Board of Tri-Service General Hospital (TSGHIRB No.: E202516013). All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. For this type of study formal consent is not required. The study adhered to STROBE and RECORD reporting guidelines.","order":2,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"<b>Declarations<\/b>"}},{"value":"Not applicable; no individually identifiable data are included.","order":3,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"<b>Declarations<\/b>"}},{"value":"Informed consent was waived by the IRB because the study used deidentified electronic health record data.","order":4,"name":"Ethics","label":"Consent to participate","group":{"name":"EthicsHeading","label":"<b>Declarations<\/b>"}}]}}